Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jun 14;9(6):e027816.
doi: 10.1136/bmjopen-2018-027816.

Does a novel diagnostic pathway including blood-based risk prediction and MRI-targeted biopsies outperform prostate cancer screening using prostate-specific antigen and systematic prostate biopsies? - protocol of the randomised study STHLM3MRI

Tobias Nordström  1   2 , Fredrik Jäderling  3   4 , Stefan Carlsson  5 , Markus Aly  1   3   5 , Henrik Grönberg  1 , Martin Eklund  1
Affiliations

Does a novel diagnostic pathway including blood-based risk prediction and MRI-targeted biopsies outperform prostate cancer screening using prostate-specific antigen and systematic prostate biopsies? - protocol of the randomised study STHLM3MRI

Tobias Nordström et al. BMJ Open. .

Abstract

Introduction: Prostate cancer is a leading cause of cancer death among men in the Western world. Early detection of prostate cancer has been shown to decrease mortality, but has limitations with low specificity leading to unnecessary biopsies and overdiagnosis of low-risk cancers. The STHLM3 trial has paved way for improved specificity in early detection of prostate cancer using the blood-based STHLM3 test for identifying men at increased risk of harbouring significant prostate cancer. Targeted prostate biopsies based on MRI images have shown non-inferior sensitivity to detect significant prostate cancer and decrease the number of biopsies and non-significant cancers among men referred for prostate biopsy in clinical practice. The strategy of the STHLM3-MRI project is to study an improved diagnostic pathway including an improved blood-based test for identification of men with increased risk of prostate cancer and use of MRI to select men for diagnostic workup with targeted prostate biopsies.

Methods: This study compares prostate cancer detection using prostate-specific antigen (PSA) and systematic biopsies to the improved pathway for prostate cancer detection using the STHLM3 test and targeted biopsies in a screening context. The study will recruit 10 000 participants during 1 June 2018 to 1 June 2020 combining a paired and randomised design. Participants are grouped by PSA and Stockholm3 test level. Men with Stockholm3 ≥11% or PSA ≥3 ng/mL are randomised to systematic or MRI-targeted biopsies. This protocol follows SPIRIT guidelines. Endpoints include the number of detected prostate cancers, number of performed biopsy procedures and number of performed MRIs. Additional aims include to assess the health economic consequences and development of automated image-analysis.

Ethics and dissemination: The study is approved by the regional ethical review board in Stockholm (2017-1280/31). The study findings will be published in peer-review journals. Findings will also be disseminated by conference/departmental presentations and by media.

Trial registration number: NCT03377881; Pre-results.

Keywords: magnetic resonance imaging; prostate disease; urological tumours.

PubMed Disclaimer

Conflict of interest statement

Competing interests: HG has five prostate cancer diagnostic related patents pending, has patent applications licensed to Thermo Fisher Scientific and might receive royalties from sales related to these patents. ME is named on four of these five patent applications. Karolinska Institutet collaborates with Thermo Fisher Scientific in developing the technology for the Stockholm3 test.

Figures

Figure 1
Figure 1
Study design overview of STHLM3MRI Main Study.
Figure 2
Figure 2
Timeline overview for study participants in the STHLM3MRI Main Study.
See this image and copyright information in PMC

References

    1. Ferlay J, Soerjomataram I, Dikshit R, et al. . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136 10.1002/ijc.29210 - DOI - PubMed
    1. Mistry K, Cable G. Meta-analysis of prostate-specific antigen and digital rectal examination as screening tests for prostate carcinoma. J Am Board Fam Pract 2003;16:95–101. 10.3122/jabfm.16.2.95 - DOI - PubMed
    1. Nordström T, Aly M, Clements MS, et al. . Prostate-specific antigen (PSA) testing is prevalent and increasing in Stockholm County, Sweden, Despite no recommendations for PSA screening: results from a population-based study, 2003-2011. Eur Urol 2013;63:419–25. 10.1016/j.eururo.2012.10.001 - DOI - PubMed
    1. Schröder FH, Hugosson J, Roobol MJ, et al. . Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012;366:981–90. 10.1056/NEJMoa1113135 - DOI - PMC - PubMed
    1. Hugosson J, Carlsson S, Aus G, et al. . Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010;11:725–32. 10.1016/S1470-2045(10)70146-7 - DOI - PMC - PubMed

Publication types

Associated data